source
- Alnylam cuts TTR franchise guidance, market cap loses $10.8B as shares tumble 28%Alnylam announced a reduction in its full-year revenue outlook for its transthyretin (TTR) franchise, trimming the midpoint by $200 million. The company now projects TTR therapy sales of $4.2 bill…
- Novo Nordisk's anti-inflammatory drug ziltivekimab fails to cut major heart events in Phase 3 trialNovo Nordisk reported that its investigational anti‑inflammatory antibody, ziltivekimab, did not reduce the incidence of major cardiovascular events in a pivotal Phase 3 study. The trial enrolled…